[Federal Register Volume 69, Number 51 (Tuesday, March 16, 2004)]
[Notices]
[Pages 12360-12361]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-5857]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket Number 030-04381]


Notice of Availability of Environmental Assessment and Finding of 
No Significant Impact for License Amendment for Pfizer Inc., Terre 
Haute, IN

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability of Environmental Assessment and Finding 
of No Significant Impact.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Dr. Peter J. Lee, Division of Nuclear 
Materials Safety, U.S. Nuclear Regulatory Commission, Region III, 801 
Warrenville Road, Lisle, Illinois 60532-4351; telephone (630) 829-9870; 
or by e-mail at [email protected].

SUPPLEMENTARY INFORMATION: 

I. Introduction

    The U.S. Nuclear Regulatory Commission (NRC) is considering the 
issuance of a license amendment Material License No. 13-10179-01 issued 
to Pfizer Inc. (the licensee), to terminate its license and authorize 
release of its Terra Haute, Indiana, facility for unrestricted use.
    The NRC staff has prepared an Environmental Assessment (EA) in 
support of this licensing action in accordance with the requirements of 
10 CFR part 51. Based on the EA, the NRC has concluded that a Finding 
of No Significant Impact (FONSI) is appropriate. The amendment will be 
issued following the publication of this Notice.

II. EA Summary

    The purpose of the proposed action is to terminate Pfizer Inc.'s 
license and release its Terra Haute, Indiana, facility for unrestricted 
use. The NRC authorized Pfizer Inc. to utilize labeled compounds of H-3 
and C-14 for research and development on July 17, 1964. On September 
25, 2003, Pfizer Inc. submitted a license amendment request to 
terminate its license and release its Terra Haute facility for 
unrestricted use. Pfizer Inc. has conducted surveys of the facility and 
provided information to the NRC to demonstrate that the site meets the 
license termination criteria in subpart E of 10 CFR part 20 for 
unrestricted release. The staff has examined Pfizer Inc.'s request and 
the information that the licensee has provided in support of its 
request, including the surveys performed by Pfizer Inc. to demonstrate 
compliance with 10 CFR 20.1402, ``Radiological Criteria for 
Unrestricted Use,'' in order to ensure that the NRC's decision is 
protective of the public health and safety and the environment.

III. Finding of No Significant Impact

    The staff has prepared the EA (summarized above) in support of 
Pfizer Inc.'s proposed license amendment to terminate its license and 
release the Terre Haute facility for unrestricted use. Based on its 
review, the staff has determined that the affected environment and the 
environmental impacts associated with the decommissioning of Pfizer 
Inc.'s facility are bound by the impacts evaluated by the ``Generic 
Environmental Impact Statement in Support of Rulemaking on Radiological 
Criteria for License Termination of NRC-Licensed Nuclear Facilities'' 
(NUREG-1496). Additionally, no non-radiological impacts were 
identified. The staff also finds that the proposed release for 
unrestricted use of the Pfizer Inc. facility is in compliance with the 
10 CFR 20.1402, and finds no other activities in the area that could 
result in cumulative impacts. On the basis of the EA, the staff has 
concluded that the environmental impacts from the proposed action would 
not be significant. Accordingly, the staff has determined that a FONSI 
is appropriate, and has determined that the preparation of an 
Environmental Impact Statement is not warranted.

IV. Further Information

    In accordance with 10 CFR 2.790 of the NRC's ``Rules of Practice,'' 
Pfizer Inc.'s request, the EA summarized above, and the documents 
related to this proposed action are available electronically for public 
inspection and copying from the Publicly Available Records (PARS) 
component of NRC's document system (ADAMS). ADAMS is accessible from 
the NRC Web site at http://www.nrc.gov/reading-rm/adams.html. These 
documents include Pfizer Inc.'s letter dated September 25, 2003, with 
enclosures (Accession No. ML040090414); and the EA summarized above 
(Accession No. ML040560303). These documents may also be viewed 
electronically on the public computers located at the NRC's Public 
Document Room (PDR), O 1 F21, One White Flint North, 11555 Rockville 
Pike, Rockville,

[[Page 12361]]

MD 20852. The PDR reproduction contractor will copy documents for a 
fee. Persons who do not have access to ADAMS or who encounter problems 
in accessing the documents located in ADAMS, should contact the NRC PDR 
reference staff by telephone at 1-800-397-4209 or (301) 415-4737, or by 
e-mail to [email protected].

    Dated at Lisle, Illinois, this 25th day of February, 2004.
Christopher G. Miller,
Chief, Decommissioning Branch, Division of Nuclear Materials Safety, 
RIII.
[FR Doc. 04-5857 Filed 3-15-04; 8:45 am]
BILLING CODE 7590-01-P